陈 功

2017-06-21


毕业于上海复旦大学,随后师从中国科学院上海生理研究所冯德培院士攻读博士学位。博士毕业后先后在耶鲁大学(Dr. Anthony van den Pol) 和斯坦福大学(Dr. Richard Tsien) 进行博士后研究。现任宾夕法尼亚州立大学生物学系 维恩·魏勒曼冠名主任教授(Verne M. Willaman Chair in Life Sciences), 和暨南大学教授。研究兴趣主要集中于大脑损伤后的修复和神经退行性疾病的治疗方面,最近发表的脑内在体胶质细胞转化为功能性神经元的工作(Cell Stem Cell, BEST of 2014 article) 以及小分子化合物将人脑胶质细胞转化为神经元的工作(Cell Stem Cell, 2015)在世界范围内引起强烈反响,可能给脑疾病的治疗带来一场革命。先后在Cell Stem Cell, Nature Communications, PNASJournal of Neuroscience, Nature Cell等世界顶尖杂志发表数十篇高水平论文,并获得Alzheimer’s Association Zenith Fellows Award等多项奖励和资助。2014 11月在华盛顿主持了世界上首次干细胞领域有关在体细胞转化In vivo reprogramming)的专题报告会,参会者达800多人,标志着再生医学领域的一个新的里程碑。2016年应邀参加Shinya Yamanaka主办的10iPS细胞研讨会并作报告,介绍在体细胞转化新进展。近期又应 Neuron 杂志邀请发表了关于在体细胞转化的前瞻性综述,为这一新领域的发展指明了方向。

Dr. Gong Chen graduated from Fudan University in 1987 and obtained his PhD degree at Shanghai Institute of Physiology, Chinese Academy of Sciences. Dr. Chen did postdoctoral work first at Yale and then at Stanford University, before joining the faculty of Pennsylvania State University in 2002. Dr. Chen is now a Professor and Verne M. Willaman Chair in Life Sciences at Penn State. Dr. Chen pioneered an innovative in vivo cell conversion technology for brain and spinal cord repair. Unlike traditional stem cell transplantation therapy, Dr. Chen and his team make use of brain internal glial cells that normally surround neurons to regenerate new neurons in situ. Dr. Chen discovered that expressing a single neural transcription factor NeuroD1 in glial cells can directly convert them into functional neurons. This revolutionary work has been published in Cell Stem Cell (Guo et al., BEST of 2014 articles). Because glial cells are residential cells throughout the brain and spinal cord, Dr. Chen’s technology opens a new field that can essentially treat a wide range of neurological disorders, including traumatic brain injury such as concussion and bullet wound, stroke, Alzheimer’s disease, Parkinson’s disease, spinal cord injury, ALS, and etc. Dr. Chen and colleagues further developed a chemical conversion technology, using small molecules to convert human glial cells into functional neurons (Zhang et al., Cell Stem Cell, 2015), paving the way for a potential drug therapy to regenerate new neurons inside brains. Chen’s breakthrough findings have been widely reported in the news media, kindling new hope for millions of patients around the world. To translate his new technology from bench to the bedside, Dr. Chen and team members have filed a series of patent applications. Dr. Chen is a founder of NeuExcell Therapeutics Inc., a company aiming to lead a revolution in brain and spinal cord repair by transforming his cutting-edge technologies into therapeutic treatments to save millions of lives.

Professor Chen is a member of many professional societies, including the American Society for Neuroscience, the American Neurological Association, American Association for the Advancement of Science (AAAS), and the International Society for Stem Cell Research. He has been honored by the Alzheimer’s Association with Zenith Fellows Award. Chen has published scientific papers in high-impact journals such as Cell Stem Cell, Nature Communications, Nature, Cell, Proceedings of the National Academy of Sciences, Journal of Neuroscience, and Human Molecular Genetics. His research has been funded by U.S. National Institutes of Health, U.S. National Science Foundation, the American Heart Association, Alzheimer’s Association, and most recently U.S. Army Medical Research Program. Chen has presented invited talks and keynote speeches at many international conferences and leading institutions. Dr. Chen organized and Chaired the first symposium in history on in vivo cell conversion in the CNS at the 2014 annual meeting of Society for Neuroscience in Washington DC. This symposium is a milestone marking a new field of in vivo cell conversion in regenerative medicine.

上一篇:唐南珊
下一篇:亓 磊
Powered by 飞色网络